Product Description
RAP-219 program has blockbuster potential in epilepsy alone; follow on indications exponentially increase opportunity. RAP-219: Inhibits AMPA Currents From Hippocampal Neurons But Not From Cerebellar AMPA Neurons. (Sourced from: https://www.rapportrx.com/wp-content/uploads/2023/12/Rapport-NonConfidential-Deck_JPM-010724_FINAL.pdf)
Mechanisms of Action: AMPA Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rapport Therapeutics Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Epilepsies, Partial
Phase 1: Epilepsy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RAP-219-FOS-201 | P2 |
Not yet recruiting |
Epilepsies, Partial |
2025-03-01 |
|
| RAP-219-103 | P1 |
Not yet recruiting |
Epilepsy |
2024-09-30 |